Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR)

OBJECTIVE: To investigate the effectiveness of combining mirtazapine with serotonin-noradrenaline reuptake inhibitor (SNRI) or selective serotonin reuptake inhibitor (SSRI) antidepressants for treatment resistant depression in primary care. DESIGN: Two parallel group multicentre phase III randomised...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessler, David S, MacNeill, Stephanie J, Tallon, Deborah, Lewis, Glyn, Peters, Tim J, Hollingworth, William, Round, Jeff, Burns, Alison, Chew-Graham, Carolyn A, Anderson, Ian M, Shepherd, Tom, Campbell, John, Dickens, Chris M, Carter, Mary, Jenkinson, Caroline, Macleod, Una, Gibson, Helen, Davies, Simon, Wiles, Nicola J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207929/
https://www.ncbi.nlm.nih.gov/pubmed/30381374
http://dx.doi.org/10.1136/bmj.k4218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207929/
https://www.ncbi.nlm.nih.gov/pubmed/30381374
http://dx.doi.org/10.1136/bmj.k4218

Ejemplares similares